Neurones (NRO.PA) Stock Price

Neurones Price

Euronext·CLOSED
35.00EUR-0.40 (-1.14 %)
Market closed

Revenue has compounded at 10.4% per year over the past 19 years to 857.20 M EUR. Earnings per share have grown at 11.5% per year over the last 19 years. Neurones's net margin stands at 6.1%, broadly stable from 6.5% several years earlier. Neurones currently offers a dividend yield of about 3.71%. The payout ratio is around 61% of earnings. The dividend has grown at 17.6% per year over the past 19 years. Analysts set a median price target of 53.04 EUR, implying 51.5% above the current price. Of 5 analysts, 4 rate the stock a buy — an overall Buy consensus. The stock trades about 4% above its 52-week low.

Neurones stock price

Volume
Ex-Dividend
Details

Stock Price

ⓘ

How to Read This Chart

This chart tracks the historical stock price of Neurones over time. You can switch between daily, weekly, and monthly views and select custom time ranges — from a single day to the full available history. Use the toggle to view price changes in absolute currency terms or as a percentage change relative to the starting date.

Total Return vs. Price Return

The "Total Return" toggle includes reinvested dividends on top of the pure price movement. This is critical because dividends can account for a significant portion of long-term returns. Historically, roughly 40 % of the S&P 500's total return has come from dividends. Always compare total return when evaluating a stock's real performance against a benchmark.

Intraday Price Data

When viewing a one-day time frame, the chart displays real-time intraday price movements. This is useful for observing how Neurones stock reacts to market openings, earnings releases, or breaking news throughout the trading session.

What to Look For

Look for long-term trends (sustained upward or downward movements over months and years), support and resistance levels (price zones where the stock repeatedly bounces or reverses), and volatility (how much the price fluctuates day to day). Comparing Neurones's price chart to a market index like the S&P 500 can reveal whether the stock is outperforming or underperforming the broader market.

Neurones Stock Price History
DateNeurones Price
7/24/202635.00 EUR
7/23/202635.40 EUR
7/22/202636.00 EUR
7/21/202635.90 EUR
7/20/202635.85 EUR
7/17/202635.65 EUR
7/16/202635.85 EUR
7/15/202636.00 EUR
7/14/202635.10 EUR
7/13/202635.30 EUR
7/10/202635.00 EUR
7/9/202635.15 EUR
7/8/202635.40 EUR
7/7/202636.15 EUR
7/6/202635.30 EUR
7/3/202635.55 EUR
7/2/202635.65 EUR
7/1/202635.75 EUR
6/30/202634.55 EUR
6/29/202634.50 EUR
6/26/202633.65 EUR
6/25/202633.80 EUR
6/24/202635.10 EUR
6/23/202635.20 EUR
6/22/202635.35 EUR
6/19/202634.45 EUR
6/18/202634.05 EUR
6/17/202634.85 EUR
6/16/202635.65 EUR
6/15/202636.10 EUR
6/12/202635.45 EUR
6/11/202635.30 EUR
6/10/202636.10 EUR
6/9/202637.20 EUR
6/8/202638.45 EUR
6/5/202639.15 EUR
6/4/202638.70 EUR
6/3/202639.05 EUR
6/2/202639.55 EUR
6/1/202639.70 EUR
5/29/202639.00 EUR
5/28/202638.38 EUR
5/27/202638.05 EUR
5/26/202638.70 EUR
5/25/202639.00 EUR
5/22/202639.05 EUR
5/21/202638.60 EUR
5/20/202638.80 EUR
5/19/202638.80 EUR
5/18/202638.60 EUR
5/15/202638.05 EUR
5/14/202637.85 EUR
5/13/202637.30 EUR
5/12/202636.90 EUR
5/11/202637.15 EUR
5/8/202637.00 EUR
5/7/202637.80 EUR
5/6/202636.80 EUR
5/5/202636.20 EUR
5/4/202636.75 EUR
4/30/202635.95 EUR
4/29/202635.95 EUR
4/28/202635.65 EUR
4/27/202635.60 EUR
4/24/202636.45 EUR
4/23/202637.15 EUR
4/22/202637.45 EUR
4/21/202638.15 EUR
4/20/202638.20 EUR
4/17/202638.15 EUR
4/16/202637.05 EUR
4/15/202636.80 EUR
4/14/202636.65 EUR
4/13/202636.50 EUR
4/10/202636.00 EUR
4/9/202636.00 EUR
4/8/202636.35 EUR
4/7/202636.75 EUR
4/2/202636.11 EUR
3/27/202634.46 EUR
3/26/202634.25 EUR
3/25/202634.63 EUR
3/24/202633.60 EUR
3/23/202634.70 EUR
3/20/202634.28 EUR
3/19/202634.65 EUR
3/17/202635.12 EUR
3/16/202634.30 EUR
3/13/202634.79 EUR
3/12/202636.09 EUR
3/11/202634.86 EUR
3/10/202634.65 EUR
3/9/202634.60 EUR
3/6/202634.30 EUR
3/5/202635.00 EUR
2/26/202634.24 EUR
2/25/202633.70 EUR
2/23/202633.90 EUR
2/20/202635.22 EUR
2/19/202635.55 EUR
2/18/202635.50 EUR
2/17/202634.35 EUR
2/16/202634.82 EUR
2/13/202635.90 EUR
2/12/202636.52 EUR
2/11/202637.26 EUR
2/10/202639.28 EUR
2/9/202640.35 EUR
2/6/202639.45 EUR
2/5/202639.74 EUR
2/4/202639.20 EUR
2/3/202641.40 EUR
2/2/202641.16 EUR
1/30/202640.20 EUR
1/29/202639.45 EUR
1/28/202639.50 EUR
1/27/202639.53 EUR
1/26/202639.53 EUR
1/23/202640.05 EUR
1/22/202640.10 EUR
1/21/202640.23 EUR
1/20/202641.20 EUR
1/19/202641.33 EUR
1/16/202641.60 EUR
1/15/202642.28 EUR
1/14/202641.34 EUR
1/13/202641.93 EUR
1/12/202642.61 EUR
1/9/202642.50 EUR
1/8/202642.90 EUR
1/7/202643.10 EUR
1/6/202642.10 EUR
1/5/202642.03 EUR
1/2/202642.40 EUR
12/31/202542.55 EUR
12/30/202542.69 EUR
12/29/202542.60 EUR
12/24/202542.25 EUR
12/23/202542.60 EUR
12/22/202542.64 EUR
12/19/202542.81 EUR
12/18/202542.58 EUR
12/17/202542.95 EUR
12/16/202544.25 EUR
12/15/202544.06 EUR
12/12/202543.64 EUR
12/11/202543.70 EUR
12/10/202543.90 EUR
12/9/202544.14 EUR
12/8/202544.48 EUR
12/5/202544.30 EUR
12/4/202544.90 EUR
12/3/202544.50 EUR
12/2/202544.00 EUR
12/1/202543.80 EUR
11/28/202543.65 EUR
11/27/202543.75 EUR
11/26/202543.23 EUR
11/25/202542.60 EUR
11/24/202543.23 EUR
11/21/202542.25 EUR
11/20/202542.25 EUR
11/19/202542.03 EUR
11/18/202541.70 EUR
11/17/202542.39 EUR
11/14/202542.15 EUR
11/13/202542.65 EUR
11/12/202543.15 EUR
11/11/202543.45 EUR
11/10/202543.30 EUR
11/7/202542.35 EUR
11/6/202541.75 EUR
11/5/202538.46 EUR
11/4/202538.58 EUR
11/3/202539.00 EUR
10/31/202539.40 EUR
10/30/202539.30 EUR
10/29/202539.44 EUR
10/28/202539.61 EUR
10/27/202539.65 EUR
10/24/202539.84 EUR
10/23/202539.52 EUR
10/22/202539.51 EUR
10/21/202539.67 EUR
10/20/202539.04 EUR
10/17/202538.12 EUR
10/16/202538.00 EUR
10/15/202538.48 EUR
10/14/202538.49 EUR
10/13/202538.40 EUR
10/10/202538.91 EUR
10/9/202539.35 EUR
10/8/202539.00 EUR
10/7/202538.99 EUR
10/6/202538.35 EUR
10/3/202539.40 EUR
10/2/202538.90 EUR
10/1/202539.61 EUR
9/30/202539.75 EUR
9/29/202539.50 EUR
9/26/202538.80 EUR
9/25/202539.15 EUR
9/24/202540.10 EUR
9/23/202540.01 EUR
9/22/202539.74 EUR
9/19/202539.91 EUR
9/18/202540.44 EUR
9/17/202539.97 EUR
9/16/202539.82 EUR
9/15/202540.10 EUR
9/12/202539.55 EUR
9/11/202540.80 EUR
9/10/202541.16 EUR
9/9/202539.99 EUR
9/8/202539.58 EUR
9/5/202539.71 EUR
9/4/202539.82 EUR
9/3/202539.67 EUR
9/2/202539.83 EUR
9/1/202540.50 EUR
8/29/202540.51 EUR
8/28/202541.01 EUR
8/27/202541.40 EUR
8/26/202542.15 EUR
8/25/202543.24 EUR
8/22/202542.27 EUR
8/21/202542.13 EUR
8/20/202541.98 EUR
8/19/202542.50 EUR
8/18/202541.85 EUR
8/15/202541.00 EUR
8/14/202541.29 EUR
8/13/202542.00 EUR
8/12/202542.50 EUR
8/11/202542.50 EUR
8/8/202541.91 EUR
8/7/202542.09 EUR
8/6/202543.37 EUR
8/5/202543.28 EUR
8/4/202542.71 EUR
8/1/202542.60 EUR
7/31/202543.25 EUR
7/30/202543.20 EUR
7/29/202543.45 EUR
7/28/202543.50 EUR
Access this data via the Eulerpool API
Get Free API Key

Neurones Revenue, EBIT, Net Income

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details
Date
Revenue
EBIT
Net Income
Jan 1, 2021
579.88 M EUR
61.57 M EUR
37.71 M EUR
Jan 1, 2022
665.38 M EUR
72.89 M EUR
44.24 M EUR
Jan 1, 2023
741.18 M EUR
75.86 M EUR
49.41 M EUR
Jan 1, 2024
810.40 M EUR
77.90 M EUR
52.50 M EUR
Jan 1, 2025
857.20 M EUR
72.33 M EUR
52.07 M EUR
Jan 1, 2026 (e)
904.35 M EUR
81.81 M EUR
56.68 M EUR
Jan 1, 2027 (e)
949.56 M EUR
96.96 M EUR
62.72 M EUR
Jan 1, 2028 (e)
1.01 B EUR
100.52 M EUR
70.37 M EUR

Neurones Income Statement, Balance Sheet, Cash Flow Statement

Last updated Jul 27, 2026, 3:23 PM
 
REVENUEB EUR
REVENUE GROWTH%
GROSS MARGIN%
GROSS INCOMEM EUR
EBITM EUR
EBIT MARGIN%
NET INCOMEM EUR
NET INCOME GROWTH%
DIV.EUR
DIV. GROWTH%
SHARESM
20132014201520162017201820192020202120222023202420252026e2027e2028e
0.340.360.400.450.490.490.510.520.580.670.740.810.860.900.951.01
8.893.5012.3911.788.741.034.082.7510.5014.8511.439.315.805.484.985.90
34.4033.5235.5937.0038.3540.2042.3512.9811.9212.1846.6947.9010.5010.5010.5010.50
118.00119.00142.00165.00186.00197.00216.0068.0069.0081.00346.00388.0090.0094.9499.66105.54
32.0035.0037.0042.0044.0045.0053.0053.0061.0072.0075.0077.0072.0081.0096.00100.00
9.339.869.279.429.079.1810.3910.1110.5410.8310.129.518.408.9610.129.95
18.0020.0021.0025.0027.0025.0030.0030.0037.0044.0049.0052.0052.0056.0062.0070.00
28.5711.115.0019.058.00-7.4120.00–23.3318.9211.366.12–7.6910.7112.90
0.060.060.060.060.060.060.060.20–1.001.101.201.301.561.872.25
–––––––233.33––10.009.098.3320.0019.8720.32
23.8424.2324.2524.2424.2924.3024.2924.2724.2524.2924.3124.3524.3324.3324.3324.33
Details

Income Statement Key Figures

ⓘ

Revenue and Revenue Growth

Revenue is the starting point of every income statement — it measures the total sales Neurones generates from its core business. Revenue growth (expressed as year-over-year percentage change) is one of the most important indicators of business momentum. Sustained growth above 10 % annually is generally considered strong, while declining revenue is a serious warning sign that demands investigation.

Gross Margin

Gross margin = (Revenue − Cost of Goods Sold) ÷ Revenue. It reveals what percentage of each dollar of revenue Neurones retains after direct production costs. High gross margins (above 50 %) are typical of asset-light businesses like software and brands, while capital-intensive industries like manufacturing often operate below 30 %. Compare Neurones's gross margin to industry peers and track it over time to spot improving or deteriorating pricing power.

EBIT and EBIT Margin

EBIT measures operating profit — what remains after subtracting all operating expenses (including R&D, sales, and administrative costs) from gross profit. The EBIT margin shows this as a percentage of revenue. Because it excludes interest and taxes, EBIT allows fair comparisons between companies with different debt levels and tax jurisdictions. A rising EBIT margin indicates improving operational efficiency.

Net Income and Earnings Per Share (EPS)

Net income is the company's final profit after all expenses, interest, and taxes. Dividing net income by the number of shares outstanding gives you EPS — the single most influential metric in stock valuation. Consistent EPS growth is the primary driver of long-term stock price appreciation. Always check whether EPS growth comes from genuine profit improvement or from share buybacks reducing the share count.

Shares Outstanding

The total number of shares Neurones has issued. A declining share count (through buybacks) boosts EPS and signals management confidence. A rising share count (through stock issuance) dilutes existing shareholders. Always monitor this number alongside EPS to get the full picture of per-share value creation.

Analyst Estimates

The projected figures represent consensus estimates from professional analysts. Compare these forecasts against Neurones's historical growth rates to assess whether expectations are realistic. A company that consistently beats consensus estimates tends to see its stock price rewarded over time, while repeated misses erode investor confidence.

Neurones stock margins

The Neurones margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Neurones. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Neurones.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details
Date
Gross margin
EBIT margin
Profit margin
Jan 1, 2021
12.03 %
10.62 %
6.50 %
Jan 1, 2022
12.27 %
10.96 %
6.65 %
Jan 1, 2023
46.78 %
10.23 %
6.67 %
Jan 1, 2024
47.97 %
9.61 %
6.48 %
Jan 1, 2025
10.50 %
8.44 %
6.07 %
Jan 1, 2026 (e)
10.50 %
9.05 %
6.27 %
Jan 1, 2027 (e)
10.50 %
10.21 %
6.60 %
Jan 1, 2028 (e)
10.50 %
10.00 %
7.00 %

Neurones Stock Revenue, EBIT, Earnings per Share

The Neurones earnings per share therefore indicates how much revenue Neurones has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue per Share
EBIT per share
Earnings per Share
Details
Date
Revenue per Share
EBIT per share
Earnings per Share
Jan 1, 2021
23.91 EUR
2.54 EUR
1.55 EUR
Jan 1, 2022
27.39 EUR
3.00 EUR
1.82 EUR
Jan 1, 2023
30.49 EUR
3.12 EUR
2.03 EUR
Jan 1, 2024
33.28 EUR
3.20 EUR
2.16 EUR
Jan 1, 2025
35.24 EUR
2.97 EUR
2.14 EUR
Jan 1, 2026 (e)
37.14 EUR
3.36 EUR
2.33 EUR
Jan 1, 2027 (e)
39.00 EUR
3.99 EUR
2.58 EUR
Jan 1, 2028 (e)
41.28 EUR
4.13 EUR
2.89 EUR

Neurones business model & stock analysis

Neurones SA is a French company specializing in IT services and consulting. It was founded in 1989 and is based in Paris. With over 10,000 employees worldwide, the company operates in over 20 countries and serves clients in various industries such as healthcare, finance, telecommunications, and the public sector. Neurones SA's business model is based on developing and implementing IT projects and providing consulting and support services tailored to its clients' specific needs. The company's divisions include management consulting, system integration, maintenance, and technology services. Its product portfolio includes solutions in CRM, ERP, CMS, as well as cloud computing, cybersecurity, and data analytics. Neurones SA's key products are the Neurones AI Suite, which utilizes AI and machine learning to automate business processes and improve decision-making, and the Smart Health Platform, a cloud-based platform for the healthcare industry. The company's clients include Air France, L'Oréal, PSA Peugeot Citroën, and Orange. Neurones SA emphasizes customer loyalty, with over 80% of its clients being long-term customers. Overall, Neurones SA is a leading IT company that specializes in providing tailored IT solutions and consulting services, and it is well-positioned for future success with its global presence and diverse range of products and services.

Neurones SWOT Analysis

Strengths

Neurones SA has several strengths that contribute to its success in the market. These include:

  • Strong market presence and brand reputation
  • Diverse portfolio of innovative products and services
  • Skilled and experienced workforce
  • Solid financial performance and stability

Weaknesses

Despite its strengths, Neurones SA also faces certain weaknesses that it should address for further growth:

  • Limited geographical presence in certain markets
  • Reliance on a few key clients for a significant portion of revenue
  • Potential vulnerability to economic downturns
  • Higher operational costs compared to some competitors

Opportunities

Neurones SA can capitalize on several opportunities to expand and enhance its business:

  • Growing demand for digital transformation services
  • Emerging markets with untapped potential
  • Strategic partnerships and collaborations
  • Increasing trend towards outsourcing IT services

Threats

There are various external factors that may pose challenges to Neurones SA:

  • Intense competition from established and new players
  • Rapid technological advancements that require continuous adaptation
  • Regulatory changes impacting the industry
  • Economic and market uncertainties affecting client spending

Neurones Eulerpool Fair Value

Details

Fair Value Estimate

ⓘ

What Is Fair Value?

Fair value is an estimate of what a stock is truly "worth" based on its financial fundamentals, independent of the current market price. If the calculated fair value is above the current share price, the stock may be undervalued — and vice versa. This chart shows three different fair value approaches so you can cross-check them against each other.

Earnings-Based Fair Value

Calculated by multiplying the current earnings per share (EPS) by the average historical P/E ratio over a selected multi-year period. The smoothing over several years filters out temporary spikes or dips. If this fair value exceeds the market price, it suggests the stock is cheap relative to its earning power.

Example: Fair Value (Earnings) 2022 = EPS 2022 × Average P/E 2019–2021

Revenue-Based Fair Value

Derived by multiplying revenue per share by the average historical price-to-sales ratio. This method is particularly useful for companies with volatile or temporarily depressed earnings, as revenue tends to be more stable than profits. It answers: "At what price has the market historically valued each dollar of this company's sales?"

Example: Fair Value (Revenue) 2022 = Revenue per Share 2022 × Average P/S 2019–2021

Dividend-Based Fair Value

Calculated by dividing the dividend per share by the average historical dividend yield. This approach is most relevant for mature, consistently dividend-paying companies. If the resulting fair value is higher than the current price, it implies the stock offers a better yield than its historical average.

Example: Fair Value (Dividend) 2022 = Dividend per Share 2022 ÷ Average Yield 2019–2021

How to Use This Chart

When all three fair value lines converge above the current price, it strengthens the case that the stock is undervalued. When they diverge, investigate why — it may indicate a structural shift in margins, payout policy, or growth rate. The forward estimates on the right extend the analysis using projected fundamentals, helping you assess whether the current price already reflects future growth expectations.

Neurones historical P/E ratio, EBIT multiple, and P/S ratio

Neurones annual returns

Details

Annual Return

ⓘ

What This Chart Shows

This chart breaks down 's total annual return into two components: price return (gains or losses from stock price movement) and dividend return (income received from dividend payments). Together, they represent the total return an investor would have earned in each calendar year.

Price Return

Price return measures the percentage change in 's stock price from January 1st to December 31st of each year. Positive bars indicate the stock appreciated; negative bars show a decline. This is the component most investors focus on, but it tells only part of the story — especially for dividend-paying stocks.

Dividend Return

Dividend return represents the income generated from dividends paid during the year, expressed as a percentage of the starting stock price. While it may seem small in any single year (typically 1–4 % for established companies), dividends compound significantly over decades and have historically contributed roughly 40 % of total stock market returns.

What to Look For

Examine how many years showed positive vs. negative returns to gauge consistency. A stock with mostly positive years and small drawdowns suggests lower risk. Also compare 's annual returns to a benchmark index — consistently outperforming the market is a hallmark of a strong investment. Pay attention to the worst years: understanding downside risk is just as important as chasing upside potential.

Neurones shares outstanding

The number of shares of Neurones was 24.33 M in 2025. This indicates how many shares Neurones is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Number of stocks
Details
Date
Number of stocks
Jan 1, 2021
24.25 M Stocks
Jan 1, 2022
24.29 M Stocks
Jan 1, 2023
24.31 M Stocks
Jan 1, 2024
24.35 M Stocks
Jan 1, 2025
24.33 M Stocks
Jan 1, 2026 (e)
24.33 M Stocks
Jan 1, 2027 (e)
24.33 M Stocks
Jan 1, 2028 (e)
24.33 M Stocks

Neurones Dividend History

21 years of dividend payments · 3 consecutive increases

YearAnnual DividendYoY ChangePayments
20251.30EUR↑ 8.3%1×
Jun 11, 20251.30EUR↑ 8.3%1/1
20241.20EUR↑ 9.1%1×
20231.10EUR↑ 10.0%1×
20221.00EUR↓ 50.0%1×
20212.00EUR↑ 900.0%1×
20200.20EUR↑ 233.3%1×
20190.06EUR 0.0%1×
20180.06EUR 0.0%1×
20170.06EUR 0.0%1×
20160.06EUR 0.0%1×

Neurones dividend history and estimates

In 2025, Neurones paid a dividend amounting to 1.30 EUR. Dividend means that Neurones distributes a portion of its profits to its owners.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Dividend
Dividend (Estimate)
Special dividend
Details
Date
Dividend
Dividend (Estimate)
Special dividend
Jan 1, 2021 (e)
2.00 EUR
0.00 EUR
2.00 EUR
Jan 1, 2022
1.00 EUR
0.00 EUR
0.00 EUR
Jan 1, 2023
1.10 EUR
0.00 EUR
0.00 EUR
Jan 1, 2024
1.20 EUR
0.00 EUR
0.00 EUR
Jan 1, 2025
1.30 EUR
0.00 EUR
0.00 EUR
Jan 1, 2026 (e)
0.00 EUR
1.56 EUR
0.00 EUR
Jan 1, 2027 (e)
0.00 EUR
1.87 EUR
0.00 EUR
Jan 1, 2028 (e)
0.00 EUR
2.25 EUR
0.00 EUR

Neurones dividend payout ratio

In 2025, Neurones had a payout ratio of 60.73%. The payout ratio indicates the percentage of the company's profits that Neurones distributes as dividends.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Payout ratio
Details
Date
Payout ratio
Jan 1, 2021
128.64 %
Jan 1, 2022
54.90 %
Jan 1, 2023
54.12 %
Jan 1, 2024
55.65 %
Jan 1, 2025
60.73 %
Jan 1, 2026 (e)
67.00 %
Jan 1, 2027 (e)
72.67 %
Jan 1, 2028 (e)
77.72 %

Current Neurones forecasts and price targets in July 2026

Analyst Price Targets 2026
Δ MOM Price Target
0.00 %
Buy80.00 % (4)
Hold20.00 % (1)
Sell0.00 % (0)
12M Price Target
53.04
Last Price
35.00
Currency
EUR
12M Return Potential
51.54 %
LTM Return
0 %

Neurones shareholder structure

% Name
59.39868%
Chammard Family
Chammard Family
5.19216%
Neurones SA Management
Neurones SA Management
4.97036%
Invesco Advisers, Inc.
Invesco Advisers, Inc.
4.13614%
Family (Bertrand Ducurtil)
Family (Bertrand Ducurtil)
1.41851%
La Financière de l'Echiquier
La Financière de l'Echiquier
0.86220%
Neurones SA Employees
Neurones SA Employees

Neurones Executives and Management Board

LC

Mr. Luc De Chammard

(69)

Chairman of the Board, Chief Executive Officer · since 1984

Compensation260,000.00 EUR
BD

Mr. Bertrand Ducurtil

(65)

Executive Vice President · since 1999

Compensation260,000.00 EUR
HP

Mr. Herve Pichard

(70)

Director

Compensation5,000.00 EUR
JP

Mr. Jean-Louis Pacquement

(70)

Independent Director

Compensation5,000.00 EUR
DC

Ms. Daphne De Chammard

(76)

Director, Representative of Host Développement SAS

Compensation4,000.00 EUR

Neurones Supply Chain

Neurones Supply Chain

Correlation: how closely stock prices move together

Same directionNo relationOpposite
30 companies
#Name1M3M6M1Y2YTrend
1
Microsoft
Supplier
0.28
-0.04
0.15
0.63
0.93
2
Assicurazioni Generali
0.17
0.61
0.52
0.73
0.91
3
Eni
-0.20
-0.08
-0.25
0.64
0.90
4
Bollore
0.72
0.79
0.38
0.24
0.90
5
Rexel SA
0.08
0.57
0.07
0.36
0.88
#Name1M3M6M1Y2YTrend
1
EASYVISTA SA
Supplier
0.20
0.12
-0.19
—
—
2
Blue Prism Group Plc
Supplier
0.41
0.08
-0.28
0.09
—
3
Casino, Guichard
0.60
0.64
0.20
-0.54
-0.51
4
DocuSign
Supplier
0.10
0.16
0.20
-0.59
-0.38
5
Bechtle
Supplier
0.11
0.42
0.31
-0.02
-0.10

Frequently asked questions about Neurones

The business model of Neurones SA revolves around providing IT services and solutions to various industries. Neurones SA offers a wide range of services including consulting, system integration, infrastructure management, and software solutions. The company focuses on developing innovative and cost-effective IT solutions to help their clients optimize their business processes and improve overall performance. Neurones SA aims to meet the evolving technology needs of its clients by staying updated with the latest advancements in the IT sector. With its expertise and experience, Neurones SA strives to deliver high-quality IT services and solutions tailored to the specific requirements of each client.

All fundamentals and in-depth analysis of Neurones

Our stock analysis for Neurones stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Neurones. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.

Neurones Stock
Neurones Revenue→
Neurones Stock
Neurones Net Income→
Neurones Stock
Neurones P/E→
Neurones Stock
Neurones P/S→
Neurones Stock
Neurones EBIT→
Neurones Stock
Neurones Dividend→
Neurones Stock
Neurones Directors Dealings→
Neurones Stock
Neurones Stocks→
Neurones Stock
Neurones Market capitalization→
Neurones Stock
Neurones Debt→
Neurones Stock
Neurones Liabilities→
Neurones Stock
Neurones Equity→
Neurones Stock
Neurones AAQS→
Neurones Stock
Neurones Employees→
Neurones Stock
Neurones ROE→
Neurones Stock
Neurones ROA→
Neurones Stock
Neurones ROCE→
Neurones Stock
Neurones News→
Neurones Stock
Neurones Analyst Price Targets→

Information technology Stocks

Neurosoft Software ProductionNetwork-1 TechnologiesNeusoftNetweb Technologies IndiaNew Cosmos Electric CoNetum Group OyjNew Era Electronics CoNettlinxNew Power Plasma CoNetSol TechnologiesNew Trend International Logis-Tech CoNetskopeAll Stocks A–Z →